Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
The treatment will be administered by intramuscular or intravenous route depending on the cohort. The treatment will be administered as single dose or 3-day repeated dose. The patients will be hospitalized for 3 days and followed up to 28 days following study treatment.
Age
0–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients with uncomplicated malaria will be enrolled in cohort 1
Pediatric patients with uncomplicated malaria will be enrolled in cohort 2
Pediatric patients with severe malaria will be enrolled in cohort 3
Plasmodium falciparum malaria confirmed in blood smear
Fever within the last 24 hours.
You may not be if
Treatment with an antimalarial agent within 72h of screening
Severe concomitant disease
Pregnant or breast-feeding women
Women of child bearing potential not protected by an effective method of birth control
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
